Iroko's acute pain drug Zorvolex wins FDA approval

10/21/2013 | Reuters

Iroko Pharmaceuticals' nonsteroidal anti-inflammatory drug Zorvolex, or diclofenac, was approved by the FDA for treatment of adults with mild to moderate acute pain. Zorvolex was cleared at a 20% lower dose strength than currently available treatments, reducing the risk of strokes, acute renal failures and other serious adverse events.

View Full Article in:


Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Pompano Beach, FL